48. Primary antiphospholipid syndrome Disease details / Clinical trials / Drug dev / DR info /

24-hour ambulatory blood pressure monitoring
   Insel Gruppe AG, University Hospital Bern
      2022   -   NCT05679206   Switzerland
Acenocumarol
   Hospital Universitari Vall d'Hebron Research Institute
      2013   Phase 3   NCT02926170   Spain
ALXN1007
   ALEXION PHARMACEUTICALS INCORPORATED
      2015   Phase 2   EUCTR2013-003588-73-IT   Brazil;Canada;France;Italy;Japan;Spain;United Kingdom;United States
   Alexion Pharmaceuticals Inc.
      2015   Phase 2   EUCTR2013-003588-73-ES   Brazil;Canada;France;Italy;Japan;Spain;United Kingdom;United States
      2014   Phase 2   EUCTR2013-003588-73-GB   Spain;United Kingdom;United States
Anifrolumab
   National and Kapodistrian University of Athens
      2026   Phase 2   NCT07584083   Greece
ANTI-CD19 CAR T cell therapy
   Peking University Third Hospital
      2025   Phase 1/Phase 2   NCT06828042   China
ANTI-CD19 IL-10/IL15 CAR-NK
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2025   -   NCT06614270   China
ANTI-CD19-CAR-T cells
   First Affiliated Hospital of Wenzhou Medical University
      2024   Early Phase 1   NCT06420154   China
ANTI-CD19-CD3E-CAR-T cells
   Shanghai Changzheng Hospital
      2024   -   NCT06373081   China
ANTI-CD38 antibody injection
   Institute of Hematology & Blood Diseases Hospital, China
      2023   Phase 2   NCT05983952   China
ANTI-pandemic H1n1 influenza vaccine
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil
Antiphospholipid antibody profile
   New Valley University
      2025   -   NCT07142239   -
Antiphospholipid antibody tests
   Centre Hospitalier Universitaire de Nimes
      2013   -   NCT01649479   France
Antiplatelet drug
   Seoul National University Hospital
      2024   Phase 4   NCT05995600   Korea, Republic of
Apixaban
   Scott C. Woller, MD
      2014   Phase 4   NCT02295475   United States
Aspirin
   Nagoya City University, Graduate School of Medical Sciences
      2005   -   JPRN-UMIN000031012   Japan
   Qilu Hospital of Shandong University
      2022   -   NCT05644210   China
   Shanghai First Maternity and Infant Hospital
      2020   Phase 1   ChiCTR2000037511   China
   Shanghai General Hospital
      2020   Phase 0   ChiCTR2000035947   China
   Sugiura Mayumi
      2006   Phase 2   JPRN-jRCTs041180093   -
Aspirin 81 MG
   Ottawa Hospital Research Institute
      2017   Early Phase 1   NCT03100123   Canada
BAY 59-7939
   Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari-Università di Padova
      2014   Phase 3   EUCTR2013-004575-13-IT   Italy
BCMA-CD19 CAR-T therapy
   Peking University People's Hospital
      2024   Phase 2   NCT06794008   China
BCT301
   Peking University Third Hospital
      2025   Early Phase 1   NCT07301164   -
Belimumab
   DIPARTIMENTO DI SCIENZE CLINICHE E BIOLOGICHE (UNITO)
      2021   Phase 2   EUCTR2020-004568-25-IT   Italy
   University of Turin, Italy
      2022   Phase 2/Phase 3   NCT05020782   Italy
Belimumab+SOC
   Ruijin Hospital
      2024   Phase 2   NCT06747312   China
Benlysta
   DIPARTIMENTO DI SCIENZE CLINICHE E BIOLOGICHE (UNITO)
      2021   Phase 2   EUCTR2020-004568-25-IT   Italy
Blood draw
   University Hospital, Strasbourg, France
      2026   -   NCT07251179   France
Blood sample
   Central Hospital, Nancy, France
      2005   -   NCT02892565   -
   Hospices Civils de Lyon
      2019   -   NCT03890601   France
Blood sample collection
   Central Hospital, Nancy, France
      2018   -   NCT03348306   France
Blood test
   Central Hospital, Nancy, France
      2021   -   NCT04308564   France
   Chinese University of Hong Kong
      2022   -   NCT05583305   Hong Kong
Blood withdrawal
   Centre Hospitalier Universitaire, Amiens
      2025   -   NCT06373926   France
BRL-301
   Bioray Laboratories
      2023   -   NCT05859997   China
Calcium
   Sugiura Mayumi
      2006   Phase 2   JPRN-jRCTs041180093   -
CD19 UCAR-T cells
   Institute of Hematology & Blood Diseases Hospital, China
      2026   -   NCT07212322   China
Certolizumab pegol
   David Ware Branch
      2017   Phase 2   NCT03152058   Canada;United States
   University of Utah
      2021   Phase 2   EUCTR2020-001177-78-FR   France;United States
Cilostazol
   JASPRES team
      2006   Phase 4   JPRN-C000000342   Japan
Cimzia
   University of Utah
      2021   Phase 2   EUCTR2020-001177-78-FR   France;United States
Collectio NOF blood
   CHU de Reims
      2025   -   NCT07163338   France
Combined antithrombotic therapy
   McMaster University
      2022   -   NCT05646394   Argentina;Canada
Completion OF A questionnaire ON compliance with anticoagulant treatment
   Central Hospital, Nancy, France
      2025   -   NCT06884384   France
Completion OF A questionnaire ON satisfaction with treatment anticoagulant
   Central Hospital, Nancy, France
      2025   -   NCT06884384   France
Conventional therapy OF antiphospholipis syndrome
   Tanta University
      2020   Phase 4   NCT04274803   Egypt
Coumadin
   Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari-Università di Padova
      2014   Phase 3   EUCTR2013-004575-13-IT   Italy
Crovalimab
   Hoffmann-La Roche
      2026   Phase 2   NCT07172022   -
Danaparoid
   Nagoya City University, Graduate School of Medical Sciences
      2005   -   JPRN-UMIN000031012   Japan
Daratumumab
   National Institute of Allergy and Infectious Diseases (NIAID)
      2023   Phase 1/Phase 2   NCT05671757   United States
Dengue 1,2,3,4 (attenuated) vaccine
   University of Sao Paulo General Hospital
      2026   Phase 4   NCT07087912   Brazil
Drug inducing antiphospholipid syndrome
   Groupe Hospitalier Pitie-Salpetriere
      2019   -   NCT03994302   France
Dual antiplatelet therapy
   McMaster University
      2022   -   NCT05646394   Argentina;Canada
EA5
   Shanghai Lanyi Therapeutics Co., Ltd.
      2026   Phase 1   NCT07632976   China
Echocardiography images
   Insel Gruppe AG, University Hospital Bern
      2022   -   NCT05679206   Switzerland
Efalizumab
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal
      2008   Phase 4   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal
Enoxaparin
   Mohamed Sayed Abdelhafez
      2014   Phase 4   NCT02326051   Egypt
      2014   Phase 4   NCT02303171   Egypt
Enoxaparin 40MG plus LOW dose aspirin
   Cairo University
      2006   Phase 2   NCT01051778   Egypt
EPA and DHA supplementation
   University of Sao Paulo
      2014   -   NCT01956188   Brazil
Experimental: rivaroxaban
   University of Padova
      2014   Phase 3   NCT02157272   Italy
Fluvastatin
   Hospital for Special Surgery, New York
      2008   Phase 2   NCT00674297   United States
Heparin
   Nagoya City University, Graduate School of Medical Sciences
      2005   -   JPRN-UMIN000031012   Japan
   Shanghai First Maternity and Infant Hospital
      2020   Phase 1   ChiCTR2000037511   China
   Sugiura Mayumi
      2006   Phase 2   JPRN-jRCTs041180093   -
   Woman's Health University Hospital, Egypt
      2012   -   NCT01661439   Egypt
Heparin calcium5,000 U twice daily plus LOW dose aspirin
   Cairo University
      2006   Phase 2   NCT01051778   Egypt
Hydroxychloroquine
   Hospital for Special Surgery, New York
      2013   Phase 3   NCT01784523   United States
   National and Kapodistrian University of Athens
      2013   -   NCT04153201   Greece
   New York University School of Medicine
      2015   Phase 3   NCT02635126   United States
   Qilu Hospital of Shandong University
      2022   -   NCT05644210   China
   Shanghai General Hospital
      2020   Phase 0   ChiCTR2000035947   China
   University Hospital, Angers
      2018   Phase 3   NCT03540810   France
   University Hospital, Rouen
      2016   Phase 2   NCT02595346   France
Hydroxychloroquine sulfate
   CHU - Hôpitaux de Rouen
      2015   Phase 3   EUCTR2015-002182-38-FR   France
Hydroxychloroquine sulfate tablets
   Shanghai First Maternity and Infant Hospital
      2020   Phase 4   NCT04624269   China
Imaging assessment
   Chinese University of Hong Kong
      2022   -   NCT05583305   Hong Kong
Intralipid, 20% intravenous emulsion
   Tanta University
      2020   Phase 4   NCT04274803   Egypt
LOW dose steroids
   Imperial College London
      2005   Phase 1/Phase 2   NCT00180778   United Kingdom
LOW-molecular-weight heparin
   Ottawa Hospital Research Institute
      2017   Early Phase 1   NCT03100123   Canada
Mabthera or biosimilar rituximab
   Medical University of Vienna, Department of Internal medicine I
      2016   Phase 2   EUCTR2016-002478-11-AT   Austria
Neurosonology assessment
   Chinese University of Hong Kong
      2022   -   NCT05583305   Hong Kong
Paracetamol
   Hopital Lariboisière
      2007   Phase 4   NCT01104337   France
Plaquenil
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2020   Phase 2   EUCTR2017-004866-86-FR   France
   CHU - Hôpitaux de Rouen
      2015   Phase 3   EUCTR2015-002182-38-FR   France
Plaquenil 200MG tablet
   Assistance Publique - Hôpitaux de Paris
      2021   Phase 2   NCT04275778   France
Prednisone
   Qilu Hospital of Shandong University
      2022   -   NCT05644210   China
   Shanghai First Maternity and Infant Hospital
      2020   Phase 1   ChiCTR2000037511   China
Psychiatric evaluation
   Centre Hospitalier Universitaire de Nimes
      2013   -   NCT01649479   France
Raptiva 100 MG/ML powder and solvent FOR solution FOR injection
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal
      2008   Phase 4   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal
RAY121
   Chugai Pharmaceutical
      2024   Phase 1   NCT06723106   Australia;Austria;Bulgaria;Canada;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Spain;Taiwan;Turkey (Türkiye)
      2024   Phase 1   NCT06371417   Australia;Austria;Bulgaria;Canada;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Spain;Taiwan;Turkey (Türkiye);United States
Rituximab
   Hospital for Special Surgery, New York
      2007   Phase 2   NCT00537290   United States
   Qilu Hospital of Shandong University
      2022   -   NCT05644210   China
Rivaroxaban
   Hospital Universitari Vall d'Hebron Research Institute
      2013   Phase 3   NCT02926170   Spain
   St. Joseph's Healthcare Hamilton
      2014   Phase 4   NCT02116036   Canada
   Stéphane Zuily
      2020   -   NCT04262492   France
   University College London
      2019   Phase 2;Phase 3   EUCTR2018-001735-49-GB   United Kingdom
      2012   Phase 2   EUCTR2012-002345-38-GB   United Kingdom
   University College, London
      2021   Phase 2   NCT03684564   United Kingdom
Sirolimus
   Peking University People's Hospital
      2024   Phase 2   NCT06504420   -
Stem cell transplantation
   Richard Burt, MD
      2005   Phase 1   NCT00278616   United States
Study DRUG- ALXN1007
   Alexion Pharmaceuticals
      2014   Phase 2   NCT02128269   Brazil;Canada;Colombia;France;Italy;Japan;Korea, Republic of;Serbia;Spain;Taiwan;United Kingdom;United States
Sulfate D'hydroxychloroquine
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2020   Phase 2   EUCTR2017-004866-86-FR   France
Telitacicept
   Peking Union Medical College Hospital
      2021   Phase 2   NCT05078710   China
   Qilu Hospital of Shandong University
      2022   -   NCT05644210   China
Telitacicept+SOC
   Ruijin Hospital
      2023   Phase 2   NCT06315530   China
THE generic name IS warfarin and many producers will BE involved
   University College London
      2012   Phase 2   EUCTR2012-002345-38-GB   United Kingdom
Thrombophilia bloodwork
   Centre Hospitalier Universitaire de Nimes
      2013   -   NCT01649479   France
Ticlopidine
   JASPRES team
      2006   Phase 4   JPRN-C000000342   Japan
Trade name xarelto
   University College London
      2019   Phase 2;Phase 3   EUCTR2018-001735-49-GB   United Kingdom
      2012   Phase 2   EUCTR2012-002345-38-GB   United Kingdom
University OF turin
   DIPARTIMENTO DI SCIENZE CLINICHE E BIOLOGICHE (UNITO)
      2021   Phase 2   EUCTR2020-004568-25-IT   Italy
Usual medical management OF patients, additional blood and stool samples FOR biobanking
   Santé Arménie French-Armenian Research Center
      2023   -   NCT05904301   Armenia
Vitamin K antagonist high intensity
   McMaster University
      2022   -   NCT05646394   Argentina;Canada
Vitamin K antagonist standard intensity
   McMaster University
      2022   -   NCT05646394   Argentina;Canada
VKA
   Hoffmann-La Roche
      2026   Phase 2   NCT07172022   -
Warfarin
   JASPRES team
      2006   Phase 4   JPRN-C000000342   Japan
   Mohamed Sayed Abdelhafez
      2014   Phase 4   NCT02303171   Egypt
   Qilu Hospital of Shandong University
      2022   -   NCT05644210   China
   Scott C. Woller, MD
      2014   Phase 4   NCT02295475   United States
   Seoul National University Hospital
      2024   Phase 4   NCT05995600   Korea, Republic of
   University College, London
      2021   Phase 2   NCT03684564   United Kingdom
Warfarin sodium
   University College London
      2019   Phase 2;Phase 3   EUCTR2018-001735-49-GB   United Kingdom
Xarelto
   Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari-Università di Padova
      2014   Phase 3   EUCTR2013-004575-13-IT   Italy
YTS109 cell
   Children's Hospital of Fudan University
      2026   Phase 1   NCT07439029   China
   China Immunotech (Beijing) Biotechnology Co., Ltd.
      2025   Phase 1   NCT07236801   China
      2025   Phase 1   NCT07236762   China
      2025   Phase 1   NCT07123519   China
      2025   Phase 1   NCT07104721   China
      2025   Phase 1   NCT06978647   China
Zanubrutinib
   Institute of Hematology & Blood Diseases Hospital, China
      2022   Phase 2   NCT05199909   China